Open AccessNeuroleptic malignant syndrome in cycloserine-induced psychosis
Author(s) -
Neena Sawant,
Natasha Kate,
Swaroop Bhatankar,
Prathamesh S Kulkarni
Publication year - 2015
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.157134
Subject(s) - neuroleptic malignant syndrome , olanzapine , haloperidol , bromocriptine , cycloserine , psychosis , extrapyramidal symptoms , antipsychotic , medicine , parkinsonism , aripiprazole , adverse effect , schizophrenia (object oriented programming) , pediatrics , psychiatry , anesthesia , tuberculosis , dopamine , pathology , disease , prolactin , hormone
A 33-year-old multidrug-resistant tuberculosis female patient diagnosed as cycloserine-induced psychosis developed several neuroleptic side effects such as extrapyramidal reaction, neuroleptic malignant syndrome, and drug-induced parkinsonism while she was being treated with initially haloperidol and then olanzapine over a period of 2 months. Patient's antipsychotic medications were withdrawn, and treatment with bromocriptine showed prompt recovery. The multiple neurological adverse effects which the patient developed had implications on the management of the complications as well as her illness.